Stephen R. Wedge
Cancer Bioscience
AstraZeneca
Alderley Park
Macclesfield
United Kingdom
Name/email consistency: medium
- AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Wedge, S.R., Kendrew, J., Hennequin, L.F., Valentine, P.J., Barry, S.T., Brave, S.R., Smith, N.R., James, N.H., Dukes, M., Curwen, J.O., Chester, R., Jackson, J.A., Boffey, S.J., Kilburn, L.L., Barnett, S., Richmond, G.H., Wadsworth, P.F., Walker, M., Bigley, A.L., Taylor, S.T., Cooper, L., Beck, S., Jürgensmeier, J.M., Ogilvie, D.J. Cancer Res. (2005)
- ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Wedge, S.R., Ogilvie, D.J., Dukes, M., Kendrew, J., Chester, R., Jackson, J.A., Boffey, S.J., Valentine, P.J., Curwen, J.O., Musgrove, H.L., Graham, G.A., Hughes, G.D., Thomas, A.P., Stokes, E.S., Curry, B., Richmond, G.H., Wadsworth, P.F., Bigley, A.L., Hennequin, L.F. Cancer Res. (2002)